Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors
NCT ID: NCT01882439
Last Updated: 2017-09-15
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
395 participants
INTERVENTIONAL
2013-08-31
2016-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Treatment Sequence A
Tofacitinib 5 mg BID for 6 months
Tofacitinib
tablets, 5 mg BID x 6 months
Treatment Sequence B
Tofacitinib 10 mg BID for 6 months
Tofacitinib
tablets, 10 mg BID x 6 months
Treatment Sequence C
Placebo for 3 months then tofacitinib 5 mg BID for 3 months
Placebo
tablets, to match tofacitinib 5 mg BID x 3 months
Tofacitinib
tablets, 5 mg BID x 3 months
Treatment Sequence D
Placebo for 3 months then tofacitinib 10 mg BID for 3 months
Placebo
tablets, to match tofacitinib 10 mg BID x 3 months
Tofacitinib
tablets, 10 mg BID x 3 months
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Tofacitinib
tablets, 5 mg BID x 6 months
Tofacitinib
tablets, 10 mg BID x 6 months
Placebo
tablets, to match tofacitinib 5 mg BID x 3 months
Tofacitinib
tablets, 5 mg BID x 3 months
Placebo
tablets, to match tofacitinib 10 mg BID x 3 months
Tofacitinib
tablets, 10 mg BID x 3 months
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Active plaque psoriasis at screening
* Inadequate efficacy or lack of toleration to previously administered TNF inhibitor
Exclusion Criteria
* History of autoimmune rheumatic disease other than PsA; also prior history of or current, rheumatic inflammatory disease other than PsA
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Rheumatology Associates P.C.
Birmingham, Alabama, United States
Rheumatology Associates of North Alabama, PC
Huntsville, Alabama, United States
Arizona Arthritis & Rheumatology Associates, P.C.
Glendale, Arizona, United States
Medvin Clinical Research
Covina, California, United States
St. Jude Hospital Yorba Linda DBA St. Joseph Heritage Healthcare
Fullerton, California, United States
Ronald Reagan UCLA Medical Center, Drug Information Center
Los Angeles, California, United States
UCLA David Geffen School of Medicine
Los Angeles, California, United States
San Diego Arthritis Medical Clinic
San Diego, California, United States
Stanford Hospital and Clinics
Stanford, California, United States
New England Research Associates, LLC
Trumbull, Connecticut, United States
Rheumatology Associates of Central Florida, PA
Orlando, Florida, United States
Millennium Research
Ormond Beach, Florida, United States
Arthritis Center, Inc.
Palm Harbor, Florida, United States
Integral Rheumatology & Immunology Specialists (IRIS)
Plantation, Florida, United States
Florida Medical Clinic, P.A.
Zephyrhills, Florida, United States
St. Luke's Clinic - Rheumatology
Boise, Idaho, United States
St. Luke's Intermountain Research Center
Boise, Idaho, United States
Bluegrass Community Research, Inc
Lexington, Kentucky, United States
Klein & Associates, M.D., P.A.
Hagerstown, Maryland, United States
The Center For Rheumatology And Bone Research
Wheaton, Maryland, United States
Brigham & Women's Hospital
Boston, Massachusetts, United States
Brigham and Women's Hospital
Boston, Massachusetts, United States
Clinical Pharmacology Study Group
Worcester, Massachusetts, United States
St. Paul Rheumatology, PA
Eagan, Minnesota, United States
Clayton Medical Research
St Louis, Missouri, United States
Physician Research Collaboration, LLC
Lincoln, Nebraska, United States
Dartmouth-Hitchcock Medical Center (DHMC)
Lebanon, New Hampshire, United States
Cincinnati Rheumatic Disease Study Group, Inc.
Cincinnati, Ohio, United States
University Hospitals Case Medical Center
Cleveland, Ohio, United States
Paramount Medical Research & Consulting, LLC
Middleburg Heights, Ohio, United States
East Penn Rheumatology Associates, PC
Bethlehem, Pennsylvania, United States
Altoona Center for Clinical Research
Duncansville, Pennsylvania, United States
Low Country Rheumatology, PA
Charleston, South Carolina, United States
Arthritis Clinic
Jackson, Tennessee, United States
West Tennessee Research Institute
Jackson, Tennessee, United States
Adriana M. Pop-Moody, M.D., Clinic, P.A.
Corpus Christi, Texas, United States
Pioneer Research Solutions, Inc.
Cypress, Texas, United States
Metroplex Clinical Research Center
Dallas, Texas, United States
Drug Shipment/Storage: Investigational Drug Services
Salt Lake City, Utah, United States
University of Utah Hospital & Clinics
Salt Lake City, Utah, United States
Dynacare Laboratories
Seattle, Washington, United States
Seattle Rheumatology Associates
Seattle, Washington, United States
Swedish Medical Center
Seattle, Washington, United States
Royal Prince Alfred Hospital, Rheumatology Department
Camperdown, New South Wales, Australia
Rheumatology Research Unit
Maroochydore, Queensland, Australia
Emeritus Research Pty Ltd
Malvern East, Victoria, Australia
Hospital Erasme - Clinique Universitaire de Bruxelles
Brussels, , Belgium
ReumaClinic
Genk, , Belgium
Universitair Ziekenhuis Gent
Ghent, , Belgium
University Hospital Leuven, Department of Rheumatology
Leuven, , Belgium
ZNA Jan Palfijn
Merksem, , Belgium
CMIP: Centro Mineiro de Pesquisa Ltda /
Juiz de Fora, Minas Gerais, Brazil
CETAC - DIAGNOSTICO POR IMAGEM (image only)
Curitiba, Paraná, Brazil
EDUMED - Educacao em Saude SS LTDA.
Curitiba, Paraná, Brazil
Hospital de Clinicas de Porto Alegre (HCPA) / UFRGS
Porto Alegre, Rio Grande do Sul, Brazil
Clinica Medica Bonfiglioli Ltda. / Clinica Bonfiglioli
Campinas, São Paulo, Brazil
Radiologia ClÃnica de Campinas - RCC (Images only)
Campinas, São Paulo, Brazil
Medical Plus s.r.o.
Uherské Hradiště, , Czechia
Centre Hospitalier Sud-Francilien - Secretariat de Rhumatologie
Corbeil-Essonnes, Cedex, France
Hopital Avicenne
Bobigny, , France
Rheumazentrum Prof. Dr. med Gunther Neeck
Bad Doberan, , Germany
Charite Universitatsmedizin Berlin - Campus Charite Mitte
Berlin, , Germany
Rheumapraxis Steglitz
Berlin, , Germany
Schlosspark-Klinik
Berlin, , Germany
University Hospital of Cologne
Cologne, , Germany
Universitaetsklinikum Erlangen, Medizinische Klinik 3
Erlangen, , Germany
CIRI - Centrum für innovative Diagnostik und Therapie Rheumatologie/Immunologie (GmbH)
Frankfurt am Main, , Germany
Medizinische Universitatsklinik Freiburg
Freiburg im Breisgau, , Germany
Universitaetsklinikum Des Saarlandes Und Medizinische Fakultaet Der Universitaet Des Saarlandes
Homburg, , Germany
Elisabeth Klinik Bigge
Olsberg, , Germany
Hospital Angeles Clinica Londres
Mexico City, D.F, Mexico
Centro Integral en Reumatologia SA de CV
Guadalajara, Jalisco, Mexico
Grupo Santa Bernardette S.A. de C.V.
Guadalajara, Jalisco, Mexico
Grupo Medico Camino S.C.
Mexico City, Mexico City, Mexico
CLIDITER, S.A. de C.V.
Mexico City, Mexico City, Mexico
Universidad La Salle AC
Mexico City, Mexico City, Mexico
Medica Sur, S.A.B. de C.V. (For Emergencies Only)
Mexico City, Mexico City, Mexico
Centro de Investigacion de Tratamientos Innovadores de Sinaloa, S.C
Culiacán, Sinaloa, Mexico
Sanatorio CEMSI Chapultepec (For Emergencies Only)
Culiacán, Sinaloa, Mexico
Hospital General de Culiacan "Dr. Bernardo J. Gastelum"
Culiacán, Sinaloa, Mexico
Star Medica S.A. de C.V. (For Emergencies Only)
Merdia, Yucatán, Mexico
Institute Medico Panamericano, S.A. de C.V. (For Emergencies Only)
Mérida, Yucatán, Mexico
Unidad Reumatologica Las Americas SCP
Mérida, Yucatán, Mexico
Centro de Investigacion Clinica Pensiones
Mérida, Yucatán, Mexico
Centro Multidisciplinario para el Desarrollo
Mérida, Yucatán, Mexico
Hospital Star Medica Merida (For Emergencies Only)
Mérida, Yucatán, Mexico
Christus Muguerza del parque, S.A de C.V
Chihuahua City, , Mexico
Investigacion y Biomedicina de Chihuahua
Chihuahua City, , Mexico
Centrum Kliniczno-Badawcze J.Brzezicki, B.Gornikiewicz-Brzez
Elblag, , Poland
Centrum Radiologii for X-Ray only
Elblag, , Poland
NZOZ Centrum Reumatologiczne Indywidualna Specjalistyczna Praktyka Lekarska Lek. Med. Barbara Bazela
Elblag, , Poland
Wojewodzki Szpital Zespolony Zaklad Radiologii
Elblag, , Poland
Przychodnia Specjalistyczna Lekarskiej Spozielni Pracy "Medica" for X-Ray Only
Grodzisk Mazowiecki, , Poland
Specjalistyczne Gabinety Lekarskie "DERMED" Anna Kaszuba
Lodz, , Poland
NZOZ Lecznica MAK-MED S.C.
Nadarzyn, , Poland
Prywatna Praktyka Lekarska Prof. UM dr hab. Pawel Hrycaj
Poznan, , Poland
Reumatika Centrum Reumatologii nzoz
Warsaw, , Poland
Regional State Budgetary Healthcare Institution of Karelia Republic "Republic Hospital n.a.
Petrozavodsk, Karelia Republic, Russia
State Autonomic Healthcare Institution City Clinical Hospital # 7
Kazan', Republic of Tatarstan, Russia, Russia
SBIH of Moscow "City Clinical Hospital#1 n. a. N.I. Pirogov" of the Healthcare Department of Moscow
Moscow, , Russia
City Neurological Centre "SibNeyroMed", LLC
Novosibirsk, , Russia
Limited Liability Company Consultative Diagnostic Rheumatology Center "Healthy Joints"
Novosibirsk, , Russia
State Budget Educational Institution of Highest Professional Education
Tomsk, , Russia
State Institution of Healthcare of Yaroslavl Region
Yaroslavl, , Russia
MEDMAN s.r.o. - reumatologicka ambulancia
Martin, , Slovakia
Hospital Clinico de Santiago
Santiago de Compostela, A Coruna, Spain
Corporacio Sanitaria Parc Tauli
Sabadell, Barcelona, Spain
Hospital Universitario Marques de Valdecilla
Santander, Cantabria, Spain
Hospital Sierrallana
Torrelavega, Cantabria, Spain
Complejo Hospitalario Universitario A Coruna
A Coruña, , Spain
Hospital Universitari Vall d'Hebron
Barcelona, , Spain
Hospital Universitario Virgen Macarena
Seville, , Spain
Hospital Universitaro Y Politecnico La Fe
Valencia, , Spain
Taipei Veterans General Hospital
Taipei, Taiwan Roc, Taiwan
Buddhist Dalin Tzu Chi General Hospital
Chiayi City, , Taiwan
Chang Gung Medical Foundation-Kaohsiung Branch
Kaohsiung City, , Taiwan
Chung Shan Medical University Hospital
Taichung, , Taiwan
China Medical University Hospital
Taichung, , Taiwan
Barking Havering and Redbridge University Hospitals NHS Trust
Goodmayes, Essex, United Kingdom
Barking, Havering and Redbridge University Hospitals NHS Trust
Romford, Essex, United Kingdom
The Dudley Group NHS Foundation Trust
Dudley, West Midlands, United Kingdom
Bradford Royal Infirmary, BTHFT
Bradford, West Yorkeshire, United Kingdom
Royal United Hospitals NHS Foundation Trust
Bath, , United Kingdom
Bradford Teaching Hospitals NHS Foundation Trust
Bradford, , United Kingdom
York Hospital, York Teaching Hospital NHS Foundation Trust
York, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Gossec L, Sellas A, Gruben DC, Valderrama M, Gomez S, Kinch C, Citera G. Response to Tofacitinib in Patients with Psoriatic Arthritis and Probable Anxiety/Depressive Disorder: A Post Hoc Analysis of Phase 3 Trials. Rheumatol Ther. 2025 Oct 28. doi: 10.1007/s40744-025-00800-7. Online ahead of print.
Gladman D, Tillett W, Gruben D, Coates LC, Hahne S, Volkov M. Identification of distinct disease activity trajectories in patients with psoriatic arthritis receiving tofacitinib: a post hoc analysis of two phase 3 studies. RMD Open. 2025 Jun 3;11(2):e005250. doi: 10.1136/rmdopen-2024-005250.
Gladman DD, Dougados M, Marzo-Ortega H, Cadatal MJ, Agarwal E, Kinch CD, Nash P. Long-term tofacitinib efficacy and safety in psoriatic arthritis with or without prior biologic DMARD exposure: a post hoc analysis. Rheumatol Adv Pract. 2025 Jan 21;9(2):rkaf008. doi: 10.1093/rap/rkaf008. eCollection 2025.
Mease PJ, Orbai AM, FitzGerald O, Bedaiwi M, Dona L Fleishaker, Mundayat R, Young P, Helliwell PS. Efficacy of tofacitinib on enthesitis in patients with active psoriatic arthritis: analysis of pooled data from two phase 3 studies. Arthritis Res Ther. 2023 Aug 22;25(1):153. doi: 10.1186/s13075-023-03108-5.
Eder L, Gladman DD, Mease P, Pollock RA, Luna R, Aydin SZ, Ogdie A, Polachek A, Gruben D, Cadatal MJ, Kinch C, Strand V. Sex differences in the efficacy, safety and persistence of patients with psoriatic arthritis treated with tofacitinib: a post-hoc analysis of phase 3 trials and long-term extension. RMD Open. 2023 Mar;9(1):e002718. doi: 10.1136/rmdopen-2022-002718.
Kristensen LE, Danese S, Yndestad A, Wang C, Nagy E, Modesto I, Rivas J, Benda B. Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL Surveillance. Ann Rheum Dis. 2023 Jul;82(7):901-910. doi: 10.1136/ard-2022-223715. Epub 2023 Mar 17.
Dougados M, Taylor PC, Bingham CO 3rd, Fallon L, Brault Y, Roychoudhury S, Wang L, Kessouri M. The effect of tofacitinib on residual pain in patients with rheumatoid arthritis and psoriatic arthritis. RMD Open. 2022 Sep;8(2):e002478. doi: 10.1136/rmdopen-2022-002478.
Winthrop KL, Yndestad A, Henrohn D, Danese S, Marsal S, Galindo M, Woolcott JC, Jo H, Kwok K, Shapiro AB, Jones TV, Diehl A, Su C, Panes J, Cohen SB. Influenza Adverse Events in Patients with Rheumatoid Arthritis, Ulcerative Colitis, or Psoriatic Arthritis in the Tofacitinib Clinical Development Programs. Rheumatol Ther. 2023 Apr;10(2):357-373. doi: 10.1007/s40744-022-00507-z. Epub 2022 Dec 17.
Schneeberger EE, Citera G, Nash P, Smolen JS, Mease PJ, Soriano ER, Helling C, Szumski AE, Mundayat R, de Leon DP. Comparison of disease activity index for psoriatic arthritis (DAPSA) and minimal disease activity (MDA) targets for patients with psoriatic arthritis: A post hoc analysis of data from phase 3 tofacitinib studies. Semin Arthritis Rheum. 2023 Feb;58:152134. doi: 10.1016/j.semarthrit.2022.152134. Epub 2022 Nov 13.
de Vlam K, Mease PJ, Bushmakin AG, Fleischmann R, Ogdie A, Azevedo VF, Merola JF, Woolcott J, Cappelleri JC, Fallon L, Taylor PC. Identifying and Quantifying the Role of Inflammation in Pain Reduction for Patients With Psoriatic Arthritis Treated With Tofacitinib: A Mediation Analysis. Rheumatol Ther. 2022 Oct;9(5):1451-1464. doi: 10.1007/s40744-022-00482-5. Epub 2022 Sep 8.
Orbai AM, Mease PJ, Helliwell PS, FitzGerald O, Fleishaker DL, Mundayat R, Young P. Effect of tofacitinib on dactylitis and patient-reported outcomes in patients with active psoriatic arthritis: post-hoc analysis of phase III studies. BMC Rheumatol. 2022 Sep 1;6(1):68. doi: 10.1186/s41927-022-00298-4.
Taylor PC, Bushmakin AG, Cappelleri JC, Young P, Germino R, Merola JF, Yosipovitch G. Relationships of dermatologic symptoms and quality of life in patients with psoriatic arthritis: analysis of two tofacitinib phase III studies. J Dermatolog Treat. 2022 Aug;33(5):2614-2620. doi: 10.1080/09546634.2022.2060924. Epub 2022 Apr 11.
Gladman DD, Coates LC, Wu J, Fallon L, Bacci ED, Cappelleri JC, Bushmakin AG, Helliwell PS. Time to response for clinical and patient-reported outcomes in patients with psoriatic arthritis treated with tofacitinib, adalimumab, or placebo. Arthritis Res Ther. 2022 Feb 9;24(1):40. doi: 10.1186/s13075-022-02721-0.
Dikranian A, Gold D, Bessette L, Nash P, Azevedo VF, Wang L, Woolcott J, Shapiro AB, Szumski A, Fleishaker D, Wollenhaupt J. Frequency and Duration of Early Non-serious Adverse Events in Patients with Rheumatoid Arthritis and Psoriatic Arthritis Treated with Tofacitinib. Rheumatol Ther. 2022 Apr;9(2):411-433. doi: 10.1007/s40744-021-00405-w. Epub 2021 Dec 17.
Winthrop KL, Curtis JR, Yamaoka K, Lee EB, Hirose T, Rivas JL, Kwok K, Burmester GR. Clinical Management of Herpes Zoster in Patients With Rheumatoid Arthritis or Psoriatic Arthritis Receiving Tofacitinib Treatment. Rheumatol Ther. 2022 Feb;9(1):243-263. doi: 10.1007/s40744-021-00390-0. Epub 2021 Dec 6.
Kivitz AJ, FitzGerald O, Nash P, Pang S, Azevedo VF, Wang C, Takiya L. Efficacy and safety of tofacitinib by background methotrexate dose in psoriatic arthritis: post hoc exploratory analysis from two phase III trials. Clin Rheumatol. 2022 Feb;41(2):499-511. doi: 10.1007/s10067-021-05894-2. Epub 2021 Sep 12.
de Vlam K, Ogdie A, Bushmakin AG, Cappelleri JC, Fleischmann R, Taylor PC, Azevedo V, Fallon L, Woolcott J, Mease PJ. Median time to pain improvement and the impact of baseline pain severity on pain response in patients with psoriatic arthritis treated with tofacitinib. RMD Open. 2021 Jul;7(2):e001609. doi: 10.1136/rmdopen-2021-001609.
Coates LC, Bushmakin AG, FitzGerald O, Gladman DD, Fallon L, Cappelleri JC, Hsu MA, Helliwell PS. Relationships between psoriatic arthritis composite measures of disease activity with patient-reported outcomes in phase 3 studies of tofacitinib. Arthritis Res Ther. 2021 Mar 26;23(1):94. doi: 10.1186/s13075-021-02474-2.
Ritchlin CT, Giles JT, Ogdie A, Gomez-Reino JJ, Helliwell P, Young P, Wang C, Wu J, Romero AB, Woolcott J, Stockert L. Tofacitinib in Patients With Psoriatic Arthritis and Metabolic Syndrome: A Post hoc Analysis of Phase 3 Studies. ACR Open Rheumatol. 2020 Oct;2(10):543-554. doi: 10.1002/acr2.11166. Epub 2020 Sep 10.
Panaccione R, Isaacs JD, Chen LA, Wang W, Marren A, Kwok K, Wang L, Chan G, Su C. Characterization of Creatine Kinase Levels in Tofacitinib-Treated Patients with Ulcerative Colitis: Results from Clinical Trials. Dig Dis Sci. 2021 Aug;66(8):2732-2743. doi: 10.1007/s10620-020-06560-4. Epub 2020 Aug 20.
Burmester GR, Curtis JR, Yun H, FitzGerald O, Winthrop KL, Azevedo VF, Rigby WFC, Kanik KS, Wang C, Biswas P, Jones T, Palmetto N, Hendrikx T, Menon S, Rojo R. An Integrated Analysis of the Safety of Tofacitinib in Psoriatic Arthritis across Phase III and Long-Term Extension Studies with Comparison to Real-World Observational Data. Drug Saf. 2020 Apr;43(4):379-392. doi: 10.1007/s40264-020-00904-9.
Gladman DD, Charles-Schoeman C, McInnes IB, Veale DJ, Thiers B, Nurmohamed M, Graham D, Wang C, Jones T, Wolk R, DeMasi R. Changes in Lipid Levels and Incidence of Cardiovascular Events Following Tofacitinib Treatment in Patients With Psoriatic Arthritis: A Pooled Analysis Across Phase III and Long-Term Extension Studies. Arthritis Care Res (Hoboken). 2019 Oct;71(10):1387-1395. doi: 10.1002/acr.23930.
Cella D, Wilson H, Shalhoub H, Revicki DA, Cappelleri JC, Bushmakin AG, Kudlacz E, Hsu MA. Content validity and psychometric evaluation of Functional Assessment of Chronic Illness Therapy-Fatigue in patients with psoriatic arthritis. J Patient Rep Outcomes. 2019 May 20;3(1):30. doi: 10.1186/s41687-019-0115-4.
Strand V, de Vlam K, Covarrubias-Cobos JA, Mease PJ, Gladman DD, Chen L, Kudlacz E, Wu J, Cappelleri JC, Hendrikx T, Hsu MA. Effect of tofacitinib on patient-reported outcomes in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors in the phase III, randomised controlled trial: OPAL Beyond. RMD Open. 2019 Jan 11;5(1):e000808. doi: 10.1136/rmdopen-2018-000808. eCollection 2019.
Cella D, Wilson H, Shalhoub H, Revicki DA, Cappelleri JC, Bushmakin AG, Kudlacz E, Hsu MA. Content validity and psychometric evaluation of Functional Assessment of Chronic Illness Therapy-Fatigue in patients with psoriatic arthritis. J Patient Rep Outcomes. 2019 Jan 24;3(1):5. doi: 10.1186/s41687-019-0094-5.
Nash P, Coates LC, Fleischmann R, Papp KA, Gomez-Reino JJ, Kanik KS, Wang C, Wu J, Menon S, Hendrikx T, Ports WC. Efficacy of Tofacitinib for the Treatment of Psoriatic Arthritis: Pooled Analysis of Two Phase 3 Studies. Rheumatol Ther. 2018 Dec;5(2):567-582. doi: 10.1007/s40744-018-0131-5. Epub 2018 Nov 9.
Helliwell P, Coates LC, FitzGerald O, Nash P, Soriano ER, Elaine Husni M, Hsu MA, Kanik KS, Hendrikx T, Wu J, Kudlacz E. Disease-specific composite measures for psoriatic arthritis are highly responsive to a Janus kinase inhibitor treatment that targets multiple domains of disease. Arthritis Res Ther. 2018 Oct 29;20(1):242. doi: 10.1186/s13075-018-1739-0.
Gladman D, Rigby W, Azevedo VF, Behrens F, Blanco R, Kaszuba A, Kudlacz E, Wang C, Menon S, Hendrikx T, Kanik KS. Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors. N Engl J Med. 2017 Oct 19;377(16):1525-1536. doi: 10.1056/NEJMoa1615977.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2013-001368-46
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
A3921125
Identifier Type: -
Identifier Source: org_study_id